All In Biotech

Drug Trial Radar · NCT04835584

KRT-232 and TKI Study in Chronic Myeloid Leukemia

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)

Last checked: Nov 19, 2026Latest source record: Mar 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

109

Planned (sponsor's estimate)

Start

May 7, 2021

Primary completion

Dec 31, 2024

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Kartos Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.

Conditions

  • Chronic Myeloid Leukemia

Interventions

  • KRT-232Drug

    KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

  • DasatinibDrug

    Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

  • NilotinibDrug

    Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Maximum tolerated dose (MTD)/maximum administered dose (MAD) of KRT-232Time frame: 28 Days
  2. Part 2, Arm A and B: Major molecular response (MMR) rateTime frame: 6 months
  3. Part 2, Arm C: Major hematological response (MaHR) rateTime frame: 6 months

Locations

26 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • Texas Oncology- Sammons CC at Baylor

    Dallas, Texas · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • APHM Hopital de la Timone

    Marseille, France · Recruiting

  • Institut Paoli-Calmettes

    Marseille, France · Recruiting

  • Centre Hospitalier Lyon Sud

    Saint-Genis-Laval, France · Recruiting

  • Azienda Ospedaliero - Universitaria Mater Domini

    Catanzaro, Italy · Recruiting

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

    Meldola FC, Italy · Recruiting

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy · Recruiting

  • Policlinico di Milano Ospedale Maggiore | Fondazione IRCCS Ca' Granda

    Milan, MI, Italy · Recruiting

  • Pratia Onkologia Katowice

    Katowice, Poland · Recruiting

  • National Medical Research Center of Hematology

    Moscow, Russia · Recruiting

  • Almazov National Medical Research Center

    Saint Petersburg, Russia · Recruiting

  • Samara State Medical University

    Samara, Russia · Recruiting

  • Kyungpook National University Hospital

    Daegu, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Clínica Universidad de Navarra

    Madrid, Navarre, Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.